Overall a very positive article with some insight into the strategic vision of the company.
“ Recce has its eyes on the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) global initiative, which is offering a $1 billion reward for each new antibiotic approved, as well as increased R&D funding.“
However also looks as if a CR might be coming our way.
“January 2016. It raised A$5 million in its IPO, and the funds raised helped the complete preclinical trials and establish a manufacturing facility to prepare for phase I trials. Graham said the company has completed those goals and will raise money to conduct phase I trials. “
Ann: RECCE Antibiotic International Media Attention, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.080(21.9%) |
Mkt cap ! $128.6M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 44.5¢ | 37.5¢ | $191.2K | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12222 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 10976 | 2 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |